BioCentury
ARTICLE | Clinical News

Bupivacaine collagen sponge: Phase II data

February 18, 2013 8:00 AM UTC

Top-line data from a double-blind, U.S. Phase II trial in 50 patients undergoing herniorrhaphy via open laparotomy showed that XaraColl significantly reduced SPI scores over 24 and 72 hours post-surgery vs. placebo both at rest (p=0.001 and p=0.025, respectively) and after dynamic movement with cough (p=0.001 and p=0.03, respectively). XaraColl did not significantly reduce total opioid rescue medication used over the first 24 hours post-surgery vs. placebo (p=0.073). Patients received placebo or 2 XaraColl sponges that contained 50 mg bupivacaine each and were implanted during the surgical procedure. Data were published in the Journal of Pain Research. ...